September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Mouse models of Leber Hereditary Optic Neuropathy
Author Affiliations & Notes
  • Hong Yu
    R&D Operational Excellence, Bascom Palmer Eye Inst, Univ of Miami, Miami, Florida, United States
  • Gabriel Gaidosh
    R&D Operational Excellence, Bascom Palmer Eye Inst, Univ of Miami, Miami, Florida, United States
  • John Guy
    R&D Operational Excellence, Bascom Palmer Eye Inst, Univ of Miami, Miami, Florida, United States
  • Footnotes
    Commercial Relationships   Hong Yu, None; Gabriel Gaidosh, None; John Guy, None
  • Footnotes
    Support  NIH Grants R01 EY017141, EY012355, and P30-EY014801 and by an unrestricted grant to Bascom Palmer Eye Institute from Research to Prevent Blindness, Inc.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 783. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hong Yu, Gabriel Gaidosh, John Guy; Mouse models of Leber Hereditary Optic Neuropathy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):783.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To generate mouse models carrying mutated human G3460A ND1 (hND1G3460A) or T14484C ND6 (hND6T14484C) mtDNA

Methods : The hND1G3460 gene fused with MYC or hND6T14484C fused with HA epitope tag were cloned into self-complementary AAV backbone , under control of the mitochondrial heavy strand promoter including 3 upstream conserved sequence blocks (HSPCSB). Mitochondrial encoded Cherry (mCherry) was put downstream of the mutant genes. After packaging with mito-targeted (COX8) AAV, rAAV was injected into the adult mouse’s vitreous or was microinjected into fertilized oocytes to generate transgenic mito-mice. The expression and function of the mutant genes was assessed by qPCR, immunostaining, confocal laser-scanning ophthalmoscopy (CLSO), pattern electroretinography (PERG) and spectral domain optical coherence tomography (SD-OCT).

Results : One month after injection, the mice started to show a statistically significant decrease in PERG amplitude, compared to control mice injected with rAAV carrying only mCherry. The reduction of the amplitude, in mice injected with ND1G3460A, were 26% in one month (p=0.0007) and 27% in three months (p=0.04) postinjection, and the reduction, in mice injected with ND6T14484C, were 26% (p=0.008) and 52% (p=0.0007) in one and three months respectively. SD-OCT showed optic nerve head swelling beginning as early as in 1 month after injection. Postmortem examination 7 months after injection showed severe optic neuropathy in mice been injected with mutant genes with a marked reduction in the diameter compared to control. Using the microinjections, we generated 28 transgenic mitomice carrying hND1G3460A and 20 carrying hND6T14484C. mCHERRY fluorescence was visualized in live mitomice retina and optic nerve head with the CLSO. qPCR of mtDNA and mtRNA, revealed that mutant genes were delivered and expressed in mitomice retina, optic nerve, brain, spinal cord, liver, heart, spleen, kidney and ovary, but the differences in the levels of heteroplasmy of mutant genes relative to host mtDNA between organs was highly variable (from 10-6 to 10%) and significantly different.

Conclusions : Mutant Human ND1G3460A or ND6T14484C gene injected into the eye resulted in visual loss, optic disc edema and optic atrophy in the mouse. These models may be used for testing of potential treatments for human LHON.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.